Neogen Corp NEOG

$12.19 +0.21 (1.75%)

Valuation

Market cap
2,661,150,000
Revenue TTM
$870,400,000
Net income TTM
$-7,900,000
PE ratio
38.65
Forward PE
43.83
Profit margin
-0.91%
Debt to equity
0.37

Trading

Volume
2,652,300
Avg volume
3,532,456
Day's range
$11.82 – $12.34
Shares out
218,306,000
Stochastic %K
73%
Beta
1.79
Analysts
Strong Sell
Price target
$14.25

Price

Company profile

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural to...

Show more

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns for food producers and processors. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems used for administering antibiotics and vaccines under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin, used in dogs to assist in managing pyoderma; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis on the results from multiple locations over extended periods. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Industry
Medical Devices
Sector
Healthcare
Phone
517 372 9200
Website
https://www.neogen.com
Address
620 Lesher Place, Lansing, United States

Latest news

Stocktwits

CEOBuysDisclosures Oct 10, 1:30 AM
$NEOG CEO purchased 505 shares at $11.95 for a total of $6,035. Nassif Mikheal now owns 1,579 shares. https://ceo-buys.com
0 replies
OMM22 Oct 9, 11:22 AM
$NEOG what happened it woke up today 😂😂
0 replies
schaeffers Oct 8, 2:09 PM
$NEOG giving away its premarket gains biotech firm CSL plans to roll out the firm's plasmapheresis platform across the states by the end of 2027 The shares are up 25% ytd
0 replies
HotDiamondFingers Oct 8, 12:03 PM
gap and fade check. yesterday $NEOG gapped up about 13% premarket on a small guide raise, 11.96 to 13.56. it closed at 11.68, below the prior close. when the news only partly justifies the gap, the stock needs buyers after the open or it gets sold into. the premarket number is the opening bid, the close is the verdict. same test applies to today's big gappers.
0 replies
KryptonResearch14 Oct 7, 11:00 PM
$NEOG Neogen beat and raised, then faded: shares gapped up about 14 percent premarket and closed down 2.3 percent. The quarter: 222.8M in revenue, up 8.1 percent core, vs about 208.2M expected. Adjusted EPS 8 cents vs 5. The raise: 885 to 890M in FY27 revenue, from 880 to 885M. About a half-percent nudge at the midpoint, barely above the 883.2M consensus. The morning-after math explains the fade. Guggenheim says about 3 points of that 8.1 percent core growth was order timing and easy comps, and management expects Q2 to be the year's weakest quarter for core growth. Tracking whether the beat streak survives a clean quarter without timing help.
0 replies
OMM22 Oct 7, 7:52 PM
$NEOG APLD tonight those who are listening 15% UPSIDE just helping 🤷‍♂️🤷‍♂️🤷‍♂️
0 replies
OMM22 Oct 7, 5:12 PM
$NEOG ok good luck all silent ones & stock if nothing is happening from 17% to -3% 🤷‍♂️🤷‍♂️ its goodbye 🤷‍♂️🤷‍♂️wanted to lovely results even guidance up strange not moving today
0 replies
OMM22 Oct 7, 4:59 PM
$NEOG looks like i am all ALONE in here 🤷‍♂️ anyone 😳😳😳😳😳😳😳😳😳😳😳😳😳
0 replies